Sodium–glucose co-transporter 2 (SGLT2) inhibitors have revolutionized heart failure management by demonstrating benefits beyond glycemic control, with clinical trials such as EMPEROR-preserved and DELIVER establishing their role in reducing heart failure hospitalizations and improving cardiovascular outcomes in HFpEF patients [8, 9]. Here, SLC5A2 is linked to heart failure.